Neupharma is a young and modern company focused on innovation, in the field of rare diseases particularly cystic fibrosis, a genetic disease that affects about 30,000 people in Europe.

News

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

18 March 2021
Neupharma announces the positive conclusion of the phase 1 study, conducted at the “Azienda Ospedaliera Universitaria Integrata” of Verona, with the formulation of inhaled teicoplanin in CF patients.
Neupharma is included among the 400 companies deserving the

Neupharma is included among the 400 companies deserving the "CHAMPION OF GROWTH" Certification 2016/2019

12 October 2020
The German Quality and Finance Institute published the results of the research entitled "Champions of Growth": the aim was rewarding the 400 companies whose turnover increased most in the three-year period 2016-2019.
The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

28 September 2020
The Food and Drug Administration has granted the Pediatric Orphan Drug Designation to the inhaled formulation of Teicoplanin for patients with Cystic Fibrosis.